Halozyme Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence.

CEO

Helen I. Torley

CEOHelen I. Torley

Employees

423

Employees423

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1998

Founded1998

Employees

423

Employees423

HALO Key Statistics

Market cap

13.83B

Market cap13.83B

Price-Earnings ratio

34.90

Price-Earnings ratio34.90

Dividend yield

—

Dividend yield—

Average volume

2.19M

Average volume2.19M

High today

$122.46

High today$122.46

Low today

$120.19

Low today$120.19

Open price

$122.24

Open price$122.24

Volume

2.08M

Volume2.08M

52 Week high

$122.46

52 Week high$122.46

52 Week low

$61.23

52 Week low$61.23

Stock Snapshot

With a market cap of 13.83B, Halozyme Therapeutics(HALO) trades at $121.37. The stock has a price-to-earnings ratio of 34.90.

As of 2026-10-16, Halozyme Therapeutics(HALO) stock has fluctuated between $120.19 and $122.46. The current price stands at $121.37, placing the stock +1.0% above today's low and -0.9% off the high.

The Halozyme Therapeutics(HALO)'s current trading volume is 2.08M, compared to an average daily volume of 2.19M.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $122.46 and a 52-week low of $61.23.

HALO News

CNBC 1d

Inside Edge’s Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance - CNBC

...

Investor's Business Daily 2d

This Hot Pipeline Stock Trades In A Buy Zone With a Sizzling 6.7% Yield

Four Stocks Hit New Highs Amid Tech Meltdown 7/24/2026 Halozyme Therapeutics is at a new high on Friday with earnings due on Aug. 6. Philip Morris Internationa...

Simply Wall St 2d

Halozyme Stock Has The Bull Case Changed After Argenx Deal Expansion?

Halozyme Therapeutics reported that argenx has expanded its global collaboration and license agreement to use the ENHANZE platform on two additional exclusive t...

Analyst ratings

73%

of 11 ratings

Buy

72.7%

Hold

18.2%

Sell

9.1%

More HALO News

Zacks 3d

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and ma...

Simply Wall St 5d

What Investors Are Trying To Figure Out About Halozyme Therapeutics

Halozyme Therapeutics (HALO) just expanded its global collaboration and license deal with argenx, adding two more exclusive ENHANZE targets. The enlarged agreem...

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Kratos Defense & Security…

Micron Technology

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.